Published in HIV AIDS (Auckl) on December 17, 2014
Lipids profile among ART-naïve HIV infected patients and men who have sex with men in China: a case control study. Lipids Health Dis (2016) 0.75
Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy. Vasc Health Risk Manag (2017) 0.75
Results of a doravirine-atorvastatin drug-drug interaction study. Antimicrob Agents Chemother (2016) 0.75
Serum lipid and glucose profiles in HIV-positive Nigerian children. J Virus Erad (2017) 0.75
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet (2010) 14.24
Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med (2007) 12.93
Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab (2007) 9.77
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet (2008) 8.73
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA (2011) 8.24
Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med (2005) 6.49
Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med (2012) 6.46
Increased prevalence of hypothyroidism among human immunodeficiency virus-infected patients: a need for screening. Clin Infect Dis (2003) 2.33
State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation (2008) 2.17
Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS (2005) 2.16
Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet (2002) 2.16
Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr (2002) 1.98
Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis (2007) 1.98
Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defic Syndr (2005) 1.67
Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother (2003) 1.58
Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087. J Clin Lipidol (2010) 1.50
Statins as potential treatment for cholesterol gallstones: an attempt to understand the underlying mechanism of actions. Expert Opin Pharmacother (2011) 1.46
[Effectiveness and tolerance of atorvastatin for antiretroviral therapy-secondary dyslipemia]. Med Clin (Barc) (2006) 1.41
Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD). Drug Discov Today (2007) 1.39
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin (2006) 1.38
A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res Hum Retroviruses (2005) 1.37
Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol (2004) 1.34
Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins. AIDS (2006) 1.24
Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. Am Heart J (2004) 1.22
Current treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab (2008) 1.21
Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction. PLoS One (2013) 1.16
Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J Acquir Immune Defic Syndr (2008) 1.15
Metabolic abnormalities and viral replication are associated with biomarkers of vascular dysfunction in HIV-infected children. HIV Med (2011) 1.14
Comorbidity-related treatment outcomes among HIV-infected adults in the Bronx, NY. J Urban Health (2011) 1.12
High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS (2010) 1.07
Risk factors for fatty liver in the Multicenter AIDS Cohort Study. Am J Gastroenterol (2014) 1.06
Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148. Antivir Ther (2006) 1.05
Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy. Clin Infect Dis (2004) 1.02
Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial. J Clin Endocrinol Metab (2011) 1.00
Adverse metabolic consequences of HIV protease inhibitor therapy: the search for a central mechanism. Am J Physiol Endocrinol Metab (2001) 1.00
Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors. Curr HIV Res (2008) 1.00
An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients. AIDS (2001) 0.99
Comparative Effectiveness and Toxicity of Statins Among HIV-Infected Patients. Clin Infect Dis (2010) 0.98
High-density lipoprotein cholesterol in HIV-infected patients: evidence for an association with HIV-1 viral load, antiretroviral therapy status, and regimen composition. AIDS Patient Care STDS (2008) 0.98
Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS (2003) 0.98
Continuous increase of cardiovascular diseases, diabetes, and non-HIV related cancers as causes of death in HIV-infected individuals in Brazil: an analysis of nationwide data. PLoS One (2014) 0.98
Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV. Lipids Health Dis (2007) 0.97
Menopause symptoms in women infected with HIV: prevalence and associated factors. Gynecol Endocrinol (2007) 0.97
Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy. Clin Infect Dis (2008) 0.97
Metabolic abnormalities in adult HIV infected population on antiretroviral medication in Malaysia: a cross-sectional survey. BMC Public Health (2013) 0.96
Burden of metabolic syndrome among HIV-infected patients in Southern Ethiopia. Diabetes Metab Syndr (2014) 0.96
Aggregate risk of cardiovascular disease among adolescents perinatally infected with the human immunodeficiency virus. Circulation (2013) 0.94
Renal function and incidence of chronic kidney disease in HIV patients: a Danish cohort study. Scand J Infect Dis (2012) 0.93
Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial. AIDS (2010) 0.93
Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection. Pharmacotherapy (2000) 0.92
The kidney in HIV infection: beyond HIV-associated nephropathy. Top Antivir Med (2012) 0.92
Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study. AIDS (2005) 0.92
HIV and menopause: a review. J Womens Health (Larchmt) (2007) 0.91
Lipid-lowering agents and new onset diabetes mellitus. Expert Opin Pharmacother (2010) 0.90
HIV-1 infection in subjects older than 70: a multicenter cross-sectional assessment in Catalonia, Spain. Curr HIV Res (2009) 0.89
Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: a meta-analysis of the risk factors. Hepatology (2010) 0.88
Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir. Infection (2004) 0.88
Ezetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant. Saudi J Kidney Dis Transpl (2010) 0.88
Prevalence of metabolic syndrome among antiretroviral-naive and antiretroviral-experienced HIV-1 infected Thai adults. AIDS Patient Care STDS (2014) 0.87
Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children. Antivir Ther (2005) 0.87
Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. Atherosclerosis (2004) 0.87
Fenofibrate is effective in treating hypertriglyceridemia associated with HIV lipodystrophy. Am J Med Sci (2004) 0.86
Menopause and HIV infection: age at onset and associated factors, ANRS CO3 Aquitaine cohort. Int J STD AIDS (2011) 0.86
Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone? Ann Med (2011) 0.86
Characteristics of South African patients presenting with kidney disease in rural KwaZulu-Natal: a cross sectional study. BMC Nephrol (2014) 0.86
From nonalcoholic fatty liver to nonalcoholic steatohepatitis and cirrhosis in HIV-infected patients: diagnosis and management. Curr Opin Infect Dis (2012) 0.86
Dyslipidemia and lipid management in HIV-infected patients. Curr Opin Endocrinol Diabetes Obes (2011) 0.85
Magnitude and risk factors of non-communicable diseases among people living with HIV in Tanzania: a cross sectional study from Mbeya and Dar es Salaam regions. BMC Public Health (2014) 0.85
A review of reproductive health research, guidelines and related gaps for women living with HIV. AIDS Care (2012) 0.85
Hepatic steatosis in human immunodeficiency virus: a prospective study in patients without viral hepatitis, diabetes, or alcohol abuse. J Clin Gastroenterol (2013) 0.85
Ezetimibe combined with low-dose statin effectively lowers LDL in protease inhibitor treated patients. AIDS Patient Care STDS (2008) 0.84
Prevalence of thyroid dysfunction in Thai HIV-infected patients. Curr HIV Res (2006) 0.84
Management of protease inhibitor-associated hyperlipidemia. Am J Cardiovasc Drugs (2002) 0.84
Use of fenofibrate in the management of protease inhibitor-associated lipid abnormalities. Pharmacotherapy (2000) 0.83
A retrospective study of the lipid-lowering efficacy and safety of ezetimibe added to hydroxy methylglutaryl coenzyme A reductase therapy in HIV-infected patients with hyperlipidemia. J Clin Lipidol (2007) 0.83
Cardiovascular disease in HIV-infected patients: does HIV infection in and of itself increase cardiovascular risk? Curr Opin HIV AIDS (2008) 0.82
Aging with HIV: a practical review. Braz J Infect Dis (2013) 0.82
Pravastatin in HIV-infected patients treated with protease inhibitors: a placebo-controlled randomized study. HIV Clin Trials (2007) 0.81
Heart positive: design of a randomized controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia. Contemp Clin Trials (2006) 0.81
Availability of data on adverse reactions to antiretroviral drugs in medical charts according to the Naranjo algorithm: an example of a Brazilian historical cohort. Clin Drug Investig (2014) 0.81
Update on statins: hope for osteoporotic fracture healing treatment. Curr Drug Targets (2013) 0.80
Trabecular and cortical microarchitecture in postmenopausal HIV-infected women. Calcif Tissue Int (2013) 0.80
Short-term ezetimibe is well tolerated and effective in combination with statin therapy to treat elevated LDL cholesterol in HIV-infected patients. AIDS (2009) 0.80
Fatty liver disease is associated with underlying cardiovascular disease in HIV-infected persons(*). HIV Med (2011) 0.80
HIV lipodystrophy etiology and pathogenesis. Body composition and metabolic alterations: etiology and pathogenesis. AIDS Read (2003) 0.80
Fenofibrate in the treatment of dyslipidemia associated with HIV infection. Expert Opin Drug Metab Toxicol (2010) 0.79
Abnormal thyroid function in older men with or at risk for HIV infection. HIV Med (2008) 0.79
[Rosuvastatin for the treatment of dyslipidemia in HIV-infected patients receiving highly active antiretroviral therapy. Preliminary experience]. Enferm Infecc Microbiol Clin (2008) 0.79
Prevalence of and associated factors with chronic kidney disease in human immunodeficiency virus-infected patients in Taiwan. J Microbiol Immunol Infect (2013) 0.78
Hyperlipidemia in children with HIV infection: an emerging problem. Expert Rev Cardiovasc Ther (2003) 0.78
Non-alcoholic fatty liver disease in HIV infection associated with altered hepatic fatty acid composition. Curr HIV Res (2011) 0.78
HIV and thyroid dysfunction. Rev Endocr Metab Disord (2013) 0.78
Traditional but not HIV-related factors are associated with nonalcoholic fatty liver disease in Asian patients with HIV-1 infection. PLoS One (2014) 0.77
Concurrent use of statins and hormone therapy and risk of venous thromboembolism in postmenopausal women: a population-based case-control study. Menopause (2014) 0.77
Persistently normal alanine aminotransferase levels in HIV/HCV-coinfected patients: the role of steatosis. HIV Med (2009) 0.77
Pharmacotherapy: statins and new-onset diabetes mellitus--a matter for debate. Nat Rev Endocrinol (2012) 0.77
HIV and highly active antiretroviral therapy: dyslipidemia, metabolic aberrations, and cardiovascular risk. Prev Cardiol (2007) 0.77
Nonalcoholic Fatty liver disease and risk of diabetes and cardiovascular disease: what is important for primary care physicians? J Family Med Prim Care (2015) 0.84